Spots Global Cancer Trial Database for GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Official Title: A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Study ID: NCT00244764
Conditions
Study Description
Brief Summary: Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Detailed Description:
Eligibility
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Duarte, California, United States
GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, Orange, California, United States
GSK Investigational Site, San Francisco, California, United States
GSK Investigational Site, Aurora, Colorado, United States
GSK Investigational Site, Tucker, Georgia, United States
GSK Investigational Site, Indianapolis, Indiana, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, Cleveland, Ohio, United States
GSK Investigational Site, Cleveland, Ohio, United States
GSK Investigational Site, Nashville, Tennessee, United States
GSK Investigational Site, Dallas, Texas, United States
GSK Investigational Site, Camperdown, New South Wales, Australia
GSK Investigational Site, Kogarah, New South Wales, Australia
GSK Investigational Site, Randwick, New South Wales, Australia
GSK Investigational Site, East Melbourne, Victoria, Australia
GSK Investigational Site, Footscay, Victoria, Australia
GSK Investigational Site, Heidelberg, Victoria, Australia
GSK Investigational Site, Parkville, Victoria, Australia
GSK Investigational Site, Bruxelles, , Belgium
GSK Investigational Site, Bruxelles, , Belgium
GSK Investigational Site, Gent, , Belgium
GSK Investigational Site, Jette, , Belgium
GSK Investigational Site, Liège, , Belgium
GSK Investigational Site, Roeselare, , Belgium
GSK Investigational Site, Wilrijk, , Belgium
GSK Investigational Site, Guangzhou, Guangdong, China
GSK Investigational Site, Nanjing, Jiangsu, China
GSK Investigational Site, Jinan, Shandong, China
GSK Investigational Site, Hangzhou, Zhejiang, China
GSK Investigational Site, Beijing, , China
GSK Investigational Site, Beijing, , China
GSK Investigational Site, Shanghai, , China
GSK Investigational Site, Brno, , Czech Republic
GSK Investigational Site, Hradec Kralove, , Czech Republic
GSK Investigational Site, Praha 2, , Czech Republic
GSK Investigational Site, Hong Kong, , Hong Kong
GSK Investigational Site, Kowloon, , Hong Kong
GSK Investigational Site, Tuen Mun, , Hong Kong
GSK Investigational Site, Haifa, , Israel
GSK Investigational Site, Petach Tikva, , Israel
GSK Investigational Site, Tel Aviv, , Israel
GSK Investigational Site, Zrifin, , Israel
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
